Literature DB >> 22999923

R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway.

Chenli Lin1, Yinji Liang, Huili Zhu, Jijun Zhang, Xueyun Zhong.   

Abstract

p53 mutation is associated with "gain-of-function" capabilities of human cancers. We aim to identify p53 mutations in human glioma cells and to explore the potential mechanism for mutant p53-promoted cellular growth. Whole genomic DNA was isolated from SWO-38, a human glioma cell line and amplified for the region of exons 5, 6, and 8 in p53 gene using polymerase chain reaction (PCR). By means of direct sequencing of PCR products and alignment analysis using BLAST database, a mutation of G to C transition at codon 280 of p53 exon 8 (AGA→ACA), i.e. R280T was detected in SWO-38 cells. Knockdown of R280T mutant p53 by RNA interference inhibited the GSK-3β/PTEN associated cell proliferation, and PI3K/Akt but not Wnt/β-catenin signaling pathway was involved in this process. Furthermore, depletion or overexpression of PTEN alone did not affect cell proliferation and cell cycle, implicating the impairment of PTEN function in SWO-38 cells. However, knockdown of both PTEN and p53 mutation could significantly rescue the p53 depletion-mediated growth inhibition, suggesting that the R280T mutation in glioma may promote the proliferation through an underlying mechanism related to PTEN. Our observations indicate that the R280T mutation of p53 regulates the proliferation of human glioma cells related to the GSK-3β/PTEN pathway. These findings provide valuable insights for better understanding the molecular mechanism of uncontrolled growth of glioma cells.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999923     DOI: 10.1016/j.neulet.2012.09.022

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

2.  Development and characterization of six new human papillary thyroid carcinoma cell lines.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Junsun Ryu; Yunyun Chen; Michelle D Williams; Adel K El-Naggar; Mihai Gagea; Rebecca E Schweppe; Bryan R Haugen; Stephen Y Lai; Gary L Clayman
Journal:  J Clin Endocrinol Metab       Date:  2014-11-26       Impact factor: 5.958

Review 3.  Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors.

Authors:  Wenting Xu; Zhen Yang; Shu-Feng Zhou; Nonghua Lu
Journal:  Drug Des Devel Ther       Date:  2014-10-06       Impact factor: 4.162

4.  Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells.

Authors:  Sony Pandey; Jennifer Bourn; Maria Cekanova
Journal:  Oncotarget       Date:  2018-06-19

5.  Ubiquitin ligase RNF5 serves an important role in the development of human glioma.

Authors:  Yong Gao; Chengmin Xuan; Mingwei Jin; Qi An; Baobiao Zhuo; Xincheng Chen; Lei Wang; Yuan Wang; Qingzeng Sun; Yingchun Shi
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

Review 6.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

7.  Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells.

Authors:  Yulin Wen; Yong Zhang; Jinbang Li; Feng Luo; Zhongxi Huang; Kunping Liu
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

Review 8.  Regulating tumor suppressor genes: post-translational modifications.

Authors:  Ling Chen; Shuang Liu; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2020-06-10

Review 9.  The p53 Pathway in Glioblastoma.

Authors:  Ying Zhang; Collin Dube; Myron Gibert; Nichola Cruickshanks; Baomin Wang; Maeve Coughlan; Yanzhi Yang; Initha Setiady; Ciana Deveau; Karim Saoud; Cassandra Grello; Madison Oxford; Fang Yuan; Roger Abounader
Journal:  Cancers (Basel)       Date:  2018-09-01       Impact factor: 6.639

Review 10.  Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.

Authors:  Hui Li; Jinglin Zhang; Joanna Hung Man Tong; Anthony Wing Hung Chan; Jun Yu; Wei Kang; Ka Fai To
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.